Skip to main content

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

Completed · Phase 2 · NCT06553547

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)

At a glance

Research payments reported, 2025
$537,957
U.S. investigators named
10
Sites paid
10
Planned or actual enrollment
72

About the trial

Sponsor
Ardelyx
Tested
Tenapanor (drug), Placebo (drug)
Dates
Started 2024-07-24; completion 2026-07-07
Results posted
Not yet

This is a randomized, double-blind, placebo-controlled dose-ranging study to assess the safety and efficacy of tenapanor for treatment of the IBS-C in pediatric patients 6 to less than 12 year old.

From ClinicalTrials.gov, last updated 2026-08-19. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Ardelyx, Inc. reported $537,957 in research payments for this study in 2025 (48 payments).

Products named: Ibsrela

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.